Table 2 Demographics and clinical characteristics of participants.
| Â | Training Set | Testing Set | Total | p-value (t-test/chi-sq test) |
|---|---|---|---|---|
n | 127 | 85 | 212 | Â |
SCHZ/HC (SCHZ%) | 84/43 (66.1%) | 57/28 (67%) | 141/72 (66.5%) | 1 |
Male/Female (Male%) | 85/42 (66.9%) | 57/28 (67%) | 142/70 (70.0%) | 1 |
Age (Mean ± S.D) | 41.0 ± 9.9 | 41.3 ± 9.4 | 41.1 ± 9.7 | 0.65 |
Handedness: Right/Left/Ambidextrous (Right%) | 118/9 (92.9%) | 75/9/1 (88.2%) | 193/18/1 (91.0%) | 0.52 |
Illness Duration, in Years (Mean ± S.D) | 7.43 ± 8.1 | 7.38 ± 6.6 | 7.41 ± 7.5 | 0.19 |
PANSS Positive Symptom Score (Mean ± S.D) | 11.0 ± 3.8 | 9.82 ± 3.6 | 10.5 ± 3.8 | 0.10 |
PANSS Negative Symptom Score (Mean ± S.D) | 9.20 ± 3.1 | 8.63 ± 3.0 | 8.97 ± 3.1 | 0.16 |
PANSS Total Score (Mean ± S.D) | 40.0 ± 9.1 | 37.9 ± 7.1 | 39.7 ± 8.5 | 0.25 |
CPZ Equivalent Dosage, in mg (Mean ± S.D) | 189.1 ± 180.8 | 200.4 ± 185.8 | 193.7 ± 182.3 | 0.86 |
